CMA removes barrier to availability of vital treatments on the NHS
iStock The Competition and Markets Authority (CMA) has today issued a statement clarifying that certain types of engagements between competing drug firms working on ‘combination therapies’ will not be prioritised for investigation – making it easier for drug firms to work together to develop vital treatments for use in the NHS. The CMA’s statement comes